Fulcrum Therapeutics (FULC) PT Lowered to $14 at Oppenheimer
Tweet
Share
E-mailGet Alerts FULC Hot Sheet
Price: $3.74 --0%
Rating Summary:
4 Buy, 7 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 6 | Down: 9 | New: 42
Rating Summary:
4 Buy, 7 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 6 | Down: 9 | New: 42
Join SI Premium – FREE
Oppenheimer analyst Matthew Biegler lowered the price target on Fulcrum Therapeutics (NASDAQ: FULC) to $14.00 (from $16.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Ocugen, Inc. (OCGN) PT Raised to $10 at H.C. Wainwright
- Galp Energia SGPS SA (GALP:LI) (GLPEF) PT Raised to EUR24 at Morgan Stanley
- GRAIL, Inc. (GRAL) PT Raised to $150 at Canaccord
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
